ZVRA Touches New High - Can This Zebra Keep Galloping?

Zevra Therapeutics Inc. (ZVRA), which emerged as a commercial-stage company in 2024, is continuing its transformation into a patient-focused leader in rare disease therapeutics. The company's shares touched a 52-week high of $10.03 last week.

from RTT - Top Story https://ift.tt/zDhj7Cc
via IFTTT